Q&A: Physicians Weigh Improvements in MASLD Treatment Against Gaps in Assessment Strategies
Physician's Weekly
JUNE 24, 2025
This is a well-done and concise summary of where we are in 2024 in trying to tackle the immense public health problem of MASLD.” In March 2024, resmetirom was the first treatment for noncirrhotic MASLD approved by the FDA, which is quite exciting. MASLD is the leading reason for referral to a hepatologist in many US medical centers.
52 
Let's personalize your content